177 related articles for article (PubMed ID: 22459550)
1. Audiological monitoring for ototoxic tuberculosis, human immunodeficiency virus and cancer therapies in a developing world setting.
Harris T; Peer S; Fagan JJ
J Laryngol Otol; 2012 Jun; 126(6):548-51. PubMed ID: 22459550
[TBL] [Abstract][Full Text] [Related]
2. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss.
Reavis KM; Phillips DS; Fausti SA; Gordon JS; Helt WJ; Wilmington D; Bratt GW; Konrad-Martin D
Ear Hear; 2008 Dec; 29(6):875-93. PubMed ID: 18753950
[TBL] [Abstract][Full Text] [Related]
3. Antiretroviral therapy in sub-Saharan Africa: adherence lessons from tuberculosis and leprosy.
Reid SE; Reid CA; Vermund SH
Int J STD AIDS; 2004 Nov; 15(11):713-6. PubMed ID: 15537453
[TBL] [Abstract][Full Text] [Related]
4. Hearing health-care delivery in sub-Saharan Africa--a role for tele-audiology.
Swanepoel de W; Olusanya BO; Mars M
J Telemed Telecare; 2010; 16(2):53-6. PubMed ID: 20008052
[TBL] [Abstract][Full Text] [Related]
5. Highly active antiretroviral therapy and tuberculosis control in Africa: synergies and potential.
Harries AD; Hargreaves NJ; Chimzizi R; Salaniponi FM
Bull World Health Organ; 2002; 80(6):464-9. PubMed ID: 12132003
[TBL] [Abstract][Full Text] [Related]
6. Increased risk of aminoglycoside-induced hearing loss in MDR-TB patients with HIV coinfection.
Hong H; Budhathoki C; Farley JE
Int J Tuberc Lung Dis; 2018 Jun; 22(6):667-674. PubMed ID: 29862952
[TBL] [Abstract][Full Text] [Related]
7. Adverse outcome pathway for aminoglycoside ototoxicity in drug-resistant tuberculosis treatment.
Hong H; Dooley KE; Starbird LE; Francis HW; Farley JE
Arch Toxicol; 2019 May; 93(5):1385-1399. PubMed ID: 30963202
[TBL] [Abstract][Full Text] [Related]
8. An audiological profile of patients infected with multi-drug resistant tuberculosis at a district hospital in KwaZulu-Natal.
Appana D; Joseph L; Paken J
S Afr J Commun Disord; 2016 Nov; 63(1):e1-e12. PubMed ID: 28155306
[TBL] [Abstract][Full Text] [Related]
9. Lack of appropriate treatment for people with comorbid HIV/AIDS and epilepsy in sub-Saharan Africa.
Birbeck G; Chomba E; Ddumba E; Kauye F; Mielke J
Epilepsia; 2007 Jul; 48(7):1424-5. PubMed ID: 17635568
[No Abstract] [Full Text] [Related]
10. Tuberculosis and the human immunodeficiency virus: unholy marriage of the millennium.
Chakaya JM
East Afr Med J; 2008 Nov; 85(11):521-2. PubMed ID: 19413203
[No Abstract] [Full Text] [Related]
11. Correlation between hearing loss and peritonitis frequency and administration of ototoxic intraperitoneal antibiotics in patients with CAPD.
Tokgoz B; Somdas MA; Ucar C; Kocyigit I; Unal A; Sipahioglu MH; Oymak O; Utas C
Ren Fail; 2010 Jan; 32(2):179-84. PubMed ID: 20199179
[TBL] [Abstract][Full Text] [Related]
12. Hearing loss in the developing world: evaluating the iPhone mobile device as a screening tool.
Peer S; Fagan JJ
S Afr Med J; 2015 Jan; 105(1):35-9. PubMed ID: 26046161
[TBL] [Abstract][Full Text] [Related]
13. Research protocol: Cisplatin-associated ototoxicity amongst patients receiving cancer chemotherapy and the feasibility of an audiological monitoring program.
Paken J; Govender CD; Sewram V
BMC Womens Health; 2017 Dec; 17(1):129. PubMed ID: 29228931
[TBL] [Abstract][Full Text] [Related]
14. Time to rethink guidelines for tuberculosis treatment initiation in HIV-infected patients in developing countries.
Tattevin P
Int J Tuberc Lung Dis; 2011 Mar; 15(3):423-4. PubMed ID: 21333119
[No Abstract] [Full Text] [Related]
15. Antiretroviral drugs for tuberculosis control in the era of HIV/AIDS.
Williams BG; Dye C
Science; 2003 Sep; 301(5639):1535-7. PubMed ID: 12920302
[TBL] [Abstract][Full Text] [Related]
16. Scaling up antiretroviral therapy in Africa: learning from tuberculosis control programmes--the case of Malawi.
Libamba E; Makombe S; Harries AD; Chimzizi R; Salaniponi FM; Schouten EJ; Mpazanje R
Int J Tuberc Lung Dis; 2005 Oct; 9(10):1062-71. PubMed ID: 16229216
[TBL] [Abstract][Full Text] [Related]
17. Potential utility of empirical tuberculosis treatment for HIV-infected patients with advanced immunodeficiency in high TB-HIV burden settings.
Lawn SD; Ayles H; Egwaga S; Williams B; Mukadi YD; Santos Filho ED; Godfrey-Faussett P; Granich RM; Harries AD
Int J Tuberc Lung Dis; 2011 Mar; 15(3):287-95. PubMed ID: 21333094
[TBL] [Abstract][Full Text] [Related]
18. A clinical and epidemiologic update on the interaction between tuberculosis and human immunodeficiency virus infection in adults.
Habib AG
Ann Afr Med; 2009; 8(3):147-55. PubMed ID: 19884690
[TBL] [Abstract][Full Text] [Related]
19. Audiometric evaluation of patients treated for pulmonary tuberculosis.
Vasconcelos KA; Lima MA; Frota S; Ruffino Netto A; Kritski AL
J Bras Pneumol; 2012; 38(1):81-7. PubMed ID: 22407044
[TBL] [Abstract][Full Text] [Related]
20. [Severe opportunistic infections in HIV-positive adults in sub-Saharan Africa].
Anglaret X
Med Trop (Mars); 2006 Aug; 66(4):343-5. PubMed ID: 16999042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
